^
Association details:
| Biomarker: | CD33 positive |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | IMGN779 (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models
Excerpt:
Human CD33+ AML cell lines (HEL, MV4-11, HL60) were treated in vitro with controls, IMGN779...IMGN779 treatment induced significant growth inhibition in vitro in all CD33+ human AML cell lines tested that was dose dependent. IMGN779 cell killing was CD33 dependent....In vivo, IMGN779 administered as a single dose that ranged from 0.5 to 5 mg/kg, by antibody, was overall well tolerated in SCID mice bearing systemic human CD33+ AML (HEL-luciferase) xenografts.
DOI:
https://doi.org/10.1182/blood.V128.22.1645.1645
